Totally subcutaneous hemodialysis access: experience with the LifeSite Hemodialysis System.

Abstract

The LifeSite Hemodialysis System (Vasca, Inc., Tewksbury, MA) is totally subcutaneous, incorporating two silicone catheters positioned in the central venous system and connected to a stainless steel-titanium valve implanted in a subcutaneous pocket. A randomized trial and nonrandomized clinical experience have demonstrated lower rates of infection and longer device survival when 70% isopropyl alcohol is used as the antimicrobial solution with the LifeSite. Internal jugular vein placement with positioning of the valve on the anterior chest wall further improves results.

• Authors: Anthony J Comerota
• Journal: Vascular (Vascular) 2004 Jul-Aug Vol. 12 Issue 4 Pg. 256-62 ISSN: 1708-5381 [Print] England
• PMID: 15704320 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Silicones
• 2-Propanol

Topics

• 2-Propanol (therapeutic use)
• Blood Flow Velocity (physiology)
• Catheterization, Central Venous (adverse effects, methods)
• Diabetes Complications (complications)
• Equipment Design
• Humans
• Jugular Veins (surgery)
• Kidney Failure, Chronic (therapy)
• Prosthesis-Related Infections (etiology, prevention & control)
• Renal Dialysis (adverse effects, instrumentation, methods)
• Silicones
• Treatment Failure